Physician profile
Ehsan Ali
NPI 1548451297
$6,894.91
in general payments reported to CMS, 2019-2025
39 companies · $1,787 in 2025
The $1,787 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $254 · 2021: $612 · 2022: $1,382 · 2023: $1,066 · 2024: $1,321 · 2025: $1,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,174.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,471.54 | 2019-2025 | Otezla, Otezla, Amjevita |
| Lilly USA, LLC | $857.73 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Gilead Sciences, INC. | $496.01 | 2019-2025 | Yeztugo |
| Abbvie INC. | $495.07 | 2021-2025 | Qulipta, Botox |
| Astrazeneca Pharmaceuticals LP | $379.88 | 2024-2025 | Breztri, Airsupra |
| Viiv Healthcare Company | $373.28 | 2022-2025 | Apretude |
| Corium, LLC | $285.71 | 2023-2024 | Azstarys |
| Novo Nordisk INC | $281.87 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Supernus Pharmaceuticals, INC. | $241.81 | 2022-2024 | Qelbree, Qelbree |
| Pfizer INC. | $186.74 | 2022-2025 | |
| Heartflow, INC. | $148.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.31 | 2021-2022 | |
| Noven Therapeutics, LLC | $132.72 | 2024-2025 | Xelstrym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.85 | 2024 | Jardiance |
| Bausch Health US, LLC | $106.48 | 2024-2025 | Wellbutrin |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehsan Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.